TAVR Still Gaining Ground Among Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has become the standard of care for patients with severe aortic stenosis and high surgical risk, and it should be considered as an option for intermediate-risk patients. In recent years, the number of low-risk patients treated with TAVR has increased. This study analyzes low-risk patients from the German Aortic Valve Registry (GARY) who underwent isolated TAVR vs. surgical treatment.

All patients with a Society of Thoracic Surgeons (STS) score <4% between 2014 and 2015 were analyzed. The result was a total of 20,549 subjects: 14,487 underwent surgery and 6062 underwent TAVR.

Patients who underwent TAVR were significantly older and had more comorbidities, so propensity score matching was used to compare in-hospital mortality at 30 days and at 1 year.

TAVR patients showed significantly higher survival rates, both in-hospital and at 30 days, than patients who underwent conventional surgery (in-hospital survival for TAVR vs. surgery: 98.5% vs. 97.3%; p = 0.003; 30-day survival for TAVR vs. surgery: 98.1% vs. 97.1%; p = 0.014).


Read also: Is Alcohol Good, Bad, or Neutral for Cardiovascular Health?


At one year, mortality was similar for both methods (90.0% vs. 91.2%; p = 0.158).

Conclusion

This first GARY Registry analysis of low-risk patients showed similar mortality for surgery and transcatheter aortic valve replacement.

ehy699-libre-para-subir

Original Title: Patients at low surgical risk as defined by the Society of Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic Valve Registry (GARY).

Reference: Raffi Bekeredjian et al. European Heart Journal (2019) 40, 1323–1330.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....